BIOLARGO, INC.
Close on Oct 19, 2026
- Market cap
- $23.27M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2018 Ended Jun 30, 2018 | Aug 14, 2018 | During market hours | – | – | – |
Press releases
Announcements Biolargo filed with the SEC
EX-99.1 to Form 8-K/A
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Townhall and Second Quarter 2026 Earnings Results Call
Regulation FD disclosure · EX-99.2 to Form 8-K/A
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Transcript BioLargo Shareholder Townhall - BioLargo Discord 05/05/2026
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Reports Annual 2025 Operating and Financial Results
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo protects its intellectual property, revokes Pooph license due to failure to pay and other contract breaches
Agreement terminated · Material impairment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Provides Review of 2025 Accomplishments and Insights for Coming Year
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Cleantech Innovator BioLargo Reports Record Revenues in 2024 Annual Report
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo ’ s year-to-date revenues up 80%
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Generates Positive Operating Cash Flow on Record Quarterly Revenues for First Quarter of 2024
Regulation FD disclosure · EX-99.2 to Form 8-K
BioLargo Doubles Annual Revenues - Again
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
0:00:04.0 Speaker 1: Dennis, welcome back.
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Continues Record Setting Revenue Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Adds Linda Park and Christina Bray to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Sets Another New Quarterly Revenue Record
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Sets New Quarterly Revenue Record
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo ’ s First Quarterly Report of 2022 Highlights: Record Company-wide Revenues,
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
BioLargo Continues Growth Trend by Breaking Quarterly Revenue Record
Regulation FD disclosure · EX-99.1 to Form 8-K
BioLargo Annual Report for 2021 Highlights Active Commercial Catalysts,
Regulation FD disclosure · EX-99.1 to Form 8-K